Watermelon stomach as the first symptom of liver cirrhosis
„Watermelon stomach” jako první příznak cirhózy jater
Východiska:
Cévní ektazie žaludečního antra (GAVE) patří mezi vzácné příčiny gastrointestinálního krvácení nereagujícího na léčbu nebo anémie v důsledku nedostatku železa nejasné etiologie. GAVE je spojena s celou řadou stavů, jako je portální hypertenze, chronické onemocnění ledvin a vaskulární kolagenová onemocnění. GAVE je nejčastěji diagnostikována při gastroskopii. Typickým endoskopickým znakem jsou červené lineárně uspořádané pruhy na žaludečním antru. Pro diagnostiku je rovněž významný klinický průběh a histologické změny. Léčba GAVE využívá farmaceutické, endoskopické a chirurgické metody.
Případ:
Představujeme neobvyklý případ GAVE, která se objevila jako první příznak cirhózy jater, zjištěný intraoperativně při resekci žaludku z důvodu opakované ztráty krve. Diagnóza byla potvrzena biopsií jater. Před chirurgickým zákrokem byla provedena řada laboratorních vyšetření, CT a ultrazvukové vyšetření břicha, které však onemocnění jater neodhalily.
Klíčová slova:
argonová plazmová koagulace – krvácení – cévní ektazie žaludečního antra
Autoři deklarují, že v souvislosti s předmětem studie nemají žádné komerční zájmy.
Redakční rada potvrzuje, že rukopis práce splnil ICMJE kritéria pro publikace zasílané do biomedicínských časopisů.
Doručeno:
28. 7. 2016
Přijato:
18. 9. 2016
Authors:
M. Kukulska; I. Smoła; I. Gromny; E. Poniewierka; L. Paradowski
Authors place of work:
Department of Gastroenterology and Hepatology, Wroclaw Medical University, Poland
Published in the journal:
Gastroent Hepatol 2016; 70(5): 422-425
Category:
Digestive Endoscopy: Case Report
doi:
https://doi.org/10.14735/amgh2016422
Summary
Background:
Gastric antral vascular ectasia (GAVE), so-called watermelon stomach, is an uncommon cause of refractory gastrointestinal bleeding or iron deficiency anaemia with unclear etiology. GAVE is associated with a number of conditions such as portal hypertension, chronic kidney disease and collagen vascular diseases. Most commonly GAVE is diagnosed during gastroscopy. Red antral stripes radiating in linear arrays in the antrum are the most characteristic endoscopic feature. Furthermore, the clinical course and histological changes are equally important in the diagnostic process. The treatment of GAVE is based on medical, endoscopical and surgical methods.
Case:
We present an unusual case of GAVE which was the first symptom of liver cirrhosis detected intraoperatively during a gastric resection due to recurrent blood loss. The liver biopsy taken confirmed the diagnosis. Before the surgery, numerous laboratory tests, computed tomography scan, and abdomen ultrasound were performed which did not indicate liver disease.
Key words:
argon plasma coagulation – bleeding – gastric antral vascular ectasia
Introduction
Gastric antral vascular ectasia (GAVE), so-called watermelon stomach, is an uncommon but important cause of severe acute or chronic gastrointestinal blood loss. It occurs more frequently in women than in men, typically in middle- to old-aged females [1]. We do not yet have enough knowledge on this topic [2]. GAVE’s etiology remains unclear. The immunological background might play a role in the cause of watermelon stomach. GAVE is more frequently present in such conditions as systemic lupus, scleroderma, systemic sclerosis, pernicious anaemia and primary biliary cirrhosis [3].
The diagnosis is based on an endoscopic pattern and for doubtful cases on histology. Telltale watermelon stripes are a pathognomonic endoscopic pattern [4] as GAVE is characterised by longitudinal rows of ecstatic twisted mucosal vessels in the antrum [5]. Enlarged submucosal vessels may erode through the gastric mucosa, causing chronic blood loss and consequently anaemia [6].
Case report
We describe an unusual case of GAVE. The 66-year-old man with hypertension was admitted to the Department of Gastroenterology and Hepatology after being observed for the previous six months with anaemia, with a lowest haemoglobin level of 6 g/dL which required many blood transfusions. From gastroscopies performed during hospitalisation, haemorrhagic inflammation of antrum and cardia was diagnosed. The colonoscopy was normal. The blood test performed on admission revealed iron deficiency anaemia with a haemoglobin level of 10.0 g/dL, a haematocrit of 32.9%, thrombocytopenia, normal hepatic function and slightly prolonged prothrombin time. The gastroscopy performed during hospitalisation indicated a suspicion of GAVE as a diagnosis, as the endoscopy revealed erosive gastritis, with numerous erosions in cardia and antrum, with thickening of the gastric folds. Changes were also located within a diaphragmatic hernia.
During the procedure, tissue samples were collected for histopathological analysis. GAVE syndrome was considered as a cause of recurrent anaemia from gastrointestinal blood loss. Due to a GAVE diagnosis, the mucosa was cauterised and ablated using argon plasma coagulation (APC). The patient was discharged, with a recommendation of taking proton pump inhibitors and Sucralfate. After three weeks the patient was admitted to the clinic for a check-up. In blood morphology the haemoglobin level was stable (11.5 g/dL), but there was no visible improvement during the gastroscopy as the images were similar to those from three weeks before. A contrast computed tomography scan of the abdomen revealed a thickening of the pyloric antrum wall and hepatosplenomegaly. Due to recurring anaemia with a haemoglobin level of 5.7 g/dL and exhausted conservative treatment options, a few months later the patient underwent a total gastrectomy and cholecystectomy due to gallstones. Intraoperatively, liver cirrhosis was noticed, and a biopsy was taken. A histopathology exam confirmed GAVE, chronic active hepatitis and advanced fibrosis on the border of necrosis (incomplete cirrhosis).
Discussion
Rider et al. were the first who described GAVE in 1953. They analysed the case of a patient with chronic iron-deficiency anaemia. The gastroscopy revealed changes in the antrum. It was “fiery red with specific hyperthropic mucosal changes”. Chronic inflammation and an oedematous submucosa with dilated veins were noticed under the microscope [7]. The term watermelon stomach was first reported by Jabbari et al. [8].
GAVE is typically located in the gastric antrum, although sometimes and uncommonly it may be noticed in the cardia. Involvement of the proximal part of the stomach is also rare and unusual [9,10], but in our case it actually occurred and was located within a diaphragmatic hernia.
It is estimated that GAVE causes up to 4% of non-variceal upper gastrointestinal bleeding, as shown in a prospective study of 744 patients; 31% of these also had portal hypertension (PHT). Patients with coexisting GAVE and PHT have more diffuse gastric angiomas in endoscopic view [11].
Watermelon stomach is more common in certain health conditions such as hepatic cirrhosis, chronic renal failure, hypertension, chronic pulmonary disease and diabetes. Furthermore, it is also related to some autoimmune disorders such as Raynaud’s phenomenon, rheumatoid arthritis, polymyalgia rheumatica, primary biliary cirrhosis, and systemic sclerosis – both diffuse and limited [9,12]. Among the patients with GAVE antinuclear antibodies, anti-centromere and anti-RNA helicase II were detected [13]. There is a theory that states that those antibodies could cross-react with proteins in the mucosal and submucosal layer of the stomach [2]. Various studies show that there are some risk factors of GAVE. For instance, hypergastrinaemia, proliferation of neuroendocrine cells, changes in hormone levels of prostaglandin E2 (PGE2), 5-hydroxytryptamine and vasoactive intestinal polypeptide may be a cause of the development of GAVE [14]. The loose connection between the distal gastric mucosa and muscularis externa may be one of the possible causes of GAVE [15]. Some authors suggest that strong peristaltic movements may result in prolapsing of the antral mucosa. It can lead to blood vessel obstruction resulting in secondary fibromuscular hyperplasia and vascular ectasia [16].
About 30% of patients with GAVE have liver disease. The prevalence of GAVE in liver cirrhosis is nearly 2–3% of patients [17–19]. In our patient the cause of GAVE was at first unknown as he did not suffer from any disease which might predispose to watermelon stomach. GAVE was the first sign of identified intraoperatively liver cirrhosis, which was confirmed by histopathological exam of liver biopsy.
Chronic anaemia occurs frequently in cirrhotic patients [18], so it is important to perform a differential diagnosis and identify the cause to administer appropriate treatment. Patients can develop both GAVE and portal hypertensive gastropathy (PHG) but these are two different conditions which can cause gastrointestinal bleeding among patients with liver failure [20]. GAVE is located in the antrum, and PHG in the fundus and body of the stomach [19].
PHG is more common among liver cirrhosis patients with a prevalence of 20–80% and develops in the background of PHT [21]. The hepatic venous pressure gradient is related to the presence and severity of PHG [22].
The pathophysiology of GAVE is still unclear, nevertheless it is indisputable PHT is not involved in GAVE development, as it has been reported to occur in non-cirrhotic patients. It can be absent in up to 70% of patients. The reduction of PHT also changes the course of the disease [23]. Furthermore, it has been reported that liver transplantation, despite constant PHT, generates disappearance of the antral vascular lesion. The relationship of GAVE with liver insufficiency remains unclear but it seems to have a more significant role. It is possible that liver failure changes the metabolism of as yet unidentified substances [19].
Telltale watermelon stripes are the pathognomonic endoscopic pattern for GAVE [4], while a PHG endoscopy reveals snakeskin mucosa with diffuse red or brown spots, usually in the funds or gastric body, but sometimes a biopsy is required to differentiate GAVE from PHG [24]. In PHG, histology reveals dilated submucosal and mucosal veins, along with ectatic capillaries without inflammation or thrombi [21]. In GAVE, the presence of intravascular fibrin thrombi, mucosal inflammation, fibromuscular hyperplasia of lamina propria, epithelial regeneration, and mucosal architectural distortion is shown [25].
In the treatment of GAVE we use pharmacotherapy, endoscopic procedures and, in some cases, also surgery. However, refractory GAVE still presents a therapeutic challenge. The most common surgical type of GAVE treatment is antrectomy. There are no cases of recurrence of bleeding in the postoperative period observed. The disadvantage of this surgical approach is a high risk of mortality and morbidity. Portacaval shunts are not recommended in the treatment of GAVE [5]. The gold standard is endoscopic treatment. One of the most popular endoscopic approaches is Neodymium: yttrium-aluminium-garnet (Nd: YAG) laser or APC. The others are endoscopic band ligation, sclerotherapy with polidocanol [6] and radiofrequency ablation [26]. Another endoscopic method used to treat GAVE might be cryotherapy. It seems to provide encouraging results but larger, prospective studies are still needed [27].
The treatment of PHG is based on pharmacotherapy to reduce hepatic venous pressure gradients. The first line of treatment is non-selective β-blockers [19]. The efficiency of hormonal therapy – estrogen-progesterone, a long-acting somatostatin analogue – octreotide, methylprednisolone cyclophosphamide was also assessed. None of them appear capable of effectively controlling GAVE-related bleeding [2].
Conclusion
GAVE can be a rare cause of chronic gastrointestinal bleeding which we should consider when we exclude other causes. The diagnostic process and therapeutic management of GAVE, however, still remains a challenge, as endoscopic images are not always distinctive. GAVE can be associated with PHT, chronic kidney disease and collagen vascular diseases.
One third of patients with liver damage have detected GAVE, therefore it is important to consider that a differential diagnosis of PHG may also coexist. Both of these conditions can cause anaemia. The treatment of GAVE is often ineffective, despite using pharmacotherapy and endoscopic procedures; recurrent bleeding has been observed and in some cases a gastrectomy is needed.
The authors declare they have no potential conflicts of interest concerning drugs, products, or services used in the study.
The Editorial Board declares that the manuscript met the ICMJE „uniform requirements“ for biomedical papers.
Submitted: 28. 7. 2016
Accepted: 18. 9. 2016
Monika Kukulska
Department of Gastroenterology and Hepatology
Wroclaw Medical University
Borowska 213
50-556 Wrocław
Poland
monika.kukulska@gmail.com
Zdroje
1. Gostout CJ, Viggiano TR, Ahlquist DA et al. The clinical and endoscopic spectrum of the watermelon stomach. J Clin Gastroenterol 1992; 15 (3): 256–263.
2. Fuccio L, Mussetto A, Laterza L et al. Diag- nosis and management of gastric antral vascular ectasia. World J Gastrointest Endosc 2013; 5 (1): 6–13. doi: 10.4253/wjge.v5.i1.6.
3. Parrado RH, Lemus HN, Coral-Alvarado PX et al. Gastric antral vascular ectasia in systemic sclerosis: current concepts. Int J Rheumatol 2015; 2015: 762546. doi: 10.1155/2015/762546.
4. Khan HR, Low S, Selinger M et al. Splenic artery aneurysm rupture in pregnancy. J Coll Physicians Surg Pak 2004; 14 (5): 298–299.
5. Novitsky YW, Kercher KW, Czerniach DR et al. Watermelon stomach: pathophysiology, diagnosis, and management. J Gastrointest Surg 2003; 7 (5): 652–661.
6. Zulli C, Del Prete A, Romano M et al. Refractory gastric antral vascular ectasia: a new endoscopic approach. Eur Rev Med Pharmacol Sci 2015; 19 (21): 4119–4122.
7. Rider JA, Klotz AP, Kirsner JB. Gastritis with veno-capillary ectasia as a source of massive gastric hemorrhage. Gastroenterology 1953; 24 (1): 118–123.
8. Jabbari M, Cherry R, Lough JO et al. Gastric antral vascular ectasia: the watermelon stomach. Gastroenterology 1984; 87 (5): 1165–1170.
9. Selinger CP, Ang YS. Gastric antral vascular ectasia (GAVE): an update on clinical presentation, pathophysiology and treatment. Digestion 2008; 77 (2): 131–137. doi: 10.1159/000124339.
10. Stotzer PO, Willén R, Kilander AF. Watermelon stomach: not only an antral disease. Gastrointest Endosc 2002; 55 (7): 897–900.
11. Dulai GS, Jensen DM, Kovacs TO et al. Endoscopic treatment outcomes in watermelon stomach patients with and without portal hypertension. Endoscopy 2004; 36 (1): 68–72.
12. Beales IL. Watermelon stomach in the CREST syndrome. Postgrad Med J 1994; 70 (828): 766–767.
13. Valdez BC, Henning D, Busch RK et al. A nucleolar RNA helicase recognized by autoimmune antibodies from a patient with watermelon stomach disease. Nucleic Acids Res 1996; 24 (7): 1220–1224.
14. Lowes JR, Rode J. Neuroendocrine cell proliferations in gastric antral vascular ectasia. Gastroenterology 1989; 97 (1): 207–212.
15. Pasumarthy L, Srour J. Gastric antral vascular ectasia: an uncommon cause of GI bleeding. Practical Gastroenterology 2009; 33 (2): 34–36.
16. Quintero E, Pique JM, Bombi JA et al. Gastric mucosal vascular ectasias causing bleeding in cirrhosis. A distinct entity associated with hypergastrinemia and low serum levels of pepsinogen I. Gastroenterology 1987; 93 (5): 1054–1061.
17. Ward EM, Raimondo M, Rosser BG et al. Prevalence and natural history of gastric antral vascular ectasia in patients undergoing orthotopic liver transplantation. J Clin Gastroenterol 2004; 38 (10): 898–900.
18. Mathurin SA, Agüero AP, Dascani NA et al. Anemia in hospitalized patients with cirrhosis: prevalence, clinical relevance and predictive factors. Acta Gastroenterol Latinoam 2009; 39 (2): 103–111.
19. Vincent C, Pomier-Layrargues G, Dagenais M et al. Cure of gastric antral vascular ectasia by liver transplantation despite persistent portal hypertension: a clue for pathogenesis. Liver Transpl 2002; 8 (8): 717–720.
20. Ripoll C, Garcia-Tsao G. The management of portal hypertensive gastropathy and gastric antral vascular ectasia. Dig Liver Dis 2011; 43 (5): 345–351. doi: 10.1016/j.dld.2010.10.006.
21. Patwardhan VR, Cardenas A. Review article: the management of portal hypertensive gastropathy and gastric antral vascular ectasia in cirrhosis. Aliment Pharmacol Ther 2014; 40 (4): 354–362. doi: 10.1111/apt.12824.
22. Ripoll C, Garcia-Tsao G. Management of gastropathy and gastric vascular ectasia in portal hypertension. Clin Liver Dis 2010; 14 (2): 281–295. doi: 10.1016/j.cld.2010.03. 013.
23. Spahr L, Villeneuve JP, Dufresne MP et al. Gastric antral vascular ectasia in cirrhotic patients: absence of relation with portal hypertension. Gut 1999; 44 (5): 739–742.
24. Casas M, Calvet X, Vergara M et al. Gastric vascular lesions in cirrhosis: gastropathy and antral vascular ectasia. Gastroenterol Hepatol 2015; 38 (2): 97–107. doi: 10.1016/j.gastrohep.2014.10.005.
25. Suit PF, Petras RE, Bauer TW et al. Gastric antral vascular ectasia. A histologic and morphometric study of “the watermelon stomach”. Am J Surg Pathol 1987; 11 (10): 750–757.
26. McGorisk T, Krishnan K, Keefer L et al. Radiofrequency ablation for refractory gastric antral vascular ectasia (with video). Gastrointest Endosc 2013; 78 (4): 584–588. doi: 10.1016/j.gie.2013.04.173.
27. Yusoff I, Brennan F, Ormonde D et al. Argon plasma coagulation for treatment of watermelon stomach. Endoscopy 2002; 34 (5): 407–410.
Štítky
Paediatric gastroenterology Gastroenterology and hepatology SurgeryČlánok vyšiel v časopise
Gastroenterology and Hepatology
2016 Číslo 5
- Metamizole at a Glance and in Practice – Effective Non-Opioid Analgesic for All Ages
- Metamizole vs. Tramadol in Postoperative Analgesia
- Spasmolytic Effect of Metamizole
- Possibilities of Using Metamizole in the Treatment of Acute Primary Headaches
- Current Insights into the Antispasmodic and Analgesic Effects of Metamizole on the Gastrointestinal Tract
Najčítanejšie v tomto čísle
- Modified FOLFIRINOX in the treatment of pancreatic cancer – efficiency and toxicity
- Prehepatic portal hypertension
- Extraoeosophageal and gastrooesophageal reflux – relationship to asthma
- Total pancreatectomy and its current place in the treatment of pancreatic diseases